seed
Stage
2020
Founded
1
Investors
About
Armatus Bio is a late-preclinical stage biotech innovator developing vectorized RNAi medicines for neuromuscular disorders, focusing on conditions such as facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease type 1A (CMT1A). The company leverages advanced RNA interference technology delivered via adeno-associated virus (AAV) vectors to silence disease-causing genes.
Explore Armatus Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.